These resources provide information about ovarian, peritoneal, and fallopian tube cancers.
Last updated: August 2022
- American Cancer Society
-
The American Cancer Society provides general information on ovarian, peritoneal and fallopian tube cancers; causes, risk factors, and prevention; early detection, diagnosis, and staging; treatments and after treatment care.
- National Cancer Institute
-
The National Cancer Institute provides general information on ovarian, peritoneal and fallopian tube cancers, ovarian germ cell tumors, and ovarian low malignant potential tumors; causes and prevention; screening; stages; treatment of ovarian epithelial, fallopian tube, and peritoneal cancer for early cancer, advanced cancer or recurrent or persistent cancer; treatment of ovarian germ cell tumors by stage and for recurrent tumors; and treatment of ovarian low malignant potential tumors for early stage tumors, late stage tumors and recurrent tumors.
Ovarian, Peritoneal, and Fallopian Tube Cancers Latest Research
Drugs Approved for Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
- National Comprehensive Cancer Network
-
The National Comprehensive Cancer Network provides a comprehensive booklet with information on ovarian, peritoneal and fallopian tube cancer basics, types of ovarian cancer, testing for ovarian cancer; a treatment guide that includes stages of ovarian cancer, surgery, chemotherapy, maintenance therapy after chemotherapy, surveillance after treatment, recurrence of cancer, persistent cancer, and survivorship; and a section on making treatment decisions including shared decision making, second opinions, and questions to ask your doctors.
- Tumor Markers for Ovarian Cancer
-
Tumor Markers for Ovarian Cancer discusses multiple tumor markers used in ovarian cancer including CA-125, Alpha-fetoprotein (AFP), Beta-hCG (Beta Human Chorionic Gonadotropin), HE4, Inhibin A & B, and CEA (Carcinoembryonic antigen).
CA-125 Levels provides detailed information about the CA-125 tumor marker, a test used to assist in diagnosing and following ovarian cancer.